Stocks · Healthcare · Biotechnology
Regeneron Pharmaceuticals, Inc. REGN
$735.20 +0.05% Close, Oct 2, 2026 · NASDAQ · Market cap $75.74B
High qualityInexpensive vs sectorLow risk
Next earnings report: Oct 30, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Earnings beat analyst estimates in each of the last 5 quarters (average surprise over the last four: +19.0%).
- Revenue over the last four quarters was $15.53B, up 9.3% from a year earlier, accelerating from 5.9% a quarter earlier.
- The company holds net cash of $469.2M (cash above total debt).
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 49%
- EPS growth (TTM, YoY)Bottom 44%
- FCF growth (TTM, YoY)Bottom 34%
- Revenue growth, 3-year CAGRBottom 39%
- Revenue growth accelerationTop 22%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 16%
- Gross marginTop 25%
- Operating marginTop 9%
- Cash conversion (OCF / net income)Bottom 23%
- Accruals (lower is better)Bottom 18%
- Net debt / EBITDA (lower is better)Top 34%
- Interest coverTop 4%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 8%
- Free-cash-flow yieldTop 19%
- EBITDA / enterprise valueTop 14%
- Sales / enterprise valueBottom 49%
- P/E vs own 5-year history (lower is better)Bottom 46%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 37%
- 6-month returnBottom 39%
- 1-year return vs S&P 500Top 42%
- Distance from 52-week highTop 23%
- Trend checklist (0–4)Bottom 38%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 24%
- Consecutive EPS beatsTop 15%
- Share of analysts rating BuyBottom 38%
- Upside to consensus price targetBottom 23%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 10%
- Maximum drawdown, 3 yearsTop 35%
- Beta vs S&P 500 (lower is better)Top 20%
- Net debt / EBITDA (lower is better)Top 34%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 5.9% | 9.3% | ↑ |
| EPS growth (YoY) | 4.5% | 1.9% | ↓ |
| Gross margin | 85.6% | 84.9% | ↓ |
| Operating margin | 27.0% | 25.6% | ↓ |
| FCF margin | 27.0% | 22.7% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 9.3% | 5.9% | ↑ | Top 49% |
| EPS growth (TTM, YoY) | 1.9% | 4.5% | ↓ | Bottom 44% |
| Gross margin | 84.9% | 85.6% | ↓ | Top 25% |
| Operating margin | 25.6% | 27.0% | ↓ | Top 9% |
| Net margin | 27.9% | 31.4% | ↓ | — |
| Free-cash-flow margin | 22.7% | 27.0% | ↓ | — |
| Return on invested capital | 9.2% | — | Top 16% | |
| Revenue growth, 3-year CAGR | 5.6% | — | Bottom 39% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- 1.03×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -0.3%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 6.4%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +7.7 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- -0.08×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- 71.7×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.50%
- Net buyback yield (TTM)
- 3.36%
- Shareholder yield
- 3.86%
- Share count change, 1 year
- -1.7%
- Share count change, 3-year CAGR
- -2.1%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Jul 30, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 5
- Beats in the last 8 reports
- 7 of 8
- Average EPS surprise, last 4
- +19.0%
- Average 2-day reaction, last 8
- +0.2%
- Positive 20 days after report
- 5 of 8
Analysts
- Consensus price target
- $844.26
- Target vs current price
- +14.8%
- Analysts with a rating
- 49
- Share rating Buy or Strong Buy
- 69%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Jul 30, 2026 | +40.6% | +6.2% | +10.5% | +17.2% | — |
| Apr 29, 2026 | +6.3% | -6.2% | -4.0% | -14.2% | -10.4% |
| Jan 30, 2026 | +6.5% | -1.1% | +2.3% | +4.3% | -0.7% |
| Oct 28, 2025 | +22.6% | +11.8% | +9.7% | +30.1% | +28.7% |
| Aug 1, 2025 | +52.9% | +2.5% | +2.6% | +6.3% | +6.0% |
| Apr 29, 2025 | -4.6% | -6.9% | -1.2% | -1.2% | -7.6% |
| Feb 4, 2025 | +7.7% | +4.5% | +3.5% | +1.3% | -10.2% |
| Oct 31, 2024 | +6.6% | -9.2% | -11.5% | -18.2% | -25.5% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Jul 30, 2026 | $14.29 | $10.16 | +40.6% | $4.29B |
| Apr 29, 2026 | $9.47 | $8.91 | +6.3% | $3.61B |
| Jan 30, 2026 | $11.44 | $10.74 | +6.5% | $3.88B |
| Oct 28, 2025 | $11.83 | $9.65 | +22.6% | $3.75B |
| Aug 1, 2025 | $12.89 | $8.43 | +52.9% | $3.68B |
| Apr 29, 2025 | $8.22 | $8.62 | -4.6% | $3.03B |
| Feb 4, 2025 | $12.07 | $11.21 | +7.7% | $3.79B |
| Oct 31, 2024 | $12.46 | $11.69 | +6.6% | $3.72B |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 18.2× | 18.3× | 48th | Top 8% |
| P/E (forward) | 13.2× | — | — | — |
| EV / EBITDA | 13.1× | — | — | Top 14% |
| EV / Sales | 4.85× | — | — | Bottom 49% |
| Free-cash-flow yield | 4.65% | — | — | Top 19% |
| Earnings yield | 5.50% | — | — | Top 8% |
P/E over the past five years
Range 8.6× – 28.9× since Jun 30, 2021. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
What moved the stock over the past year
- Price return, 1 year
- +22.5%
- Earnings per share growth (TTM)
- +1.9%
- Change in P/E multiple
- +29.7%
Most of the move came from a change in the valuation multiple.
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- +7.0%
- 200-day average slope (20 days)
- +0.6%
- Distance from 50-day average
- -6.3%
- Distance from 200-day average
- -0.1%
- RSI (14)
- 34.9
- Relative volume
- 0.82×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 30.4%
- Volatility vs own 5-year history
- 65th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.59
- Correlation with S&P 500
- 0.24
- Current drawdown from 1-year high
- -13.7%
- Maximum drawdown, 3 years
- -59.8%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Aug 27, 2024 | Jun 5, 2025 | -59.8% | 193 days | Not yet recovered |
| Oct 13, 2020 | Mar 3, 2021 | -26.5% | 96 days | 109 days (Aug 6, 2021) |
| Apr 8, 2022 | Jun 14, 2022 | -25.8% | 45 days | 77 days (Oct 4, 2022) |
| Sep 1, 2021 | Oct 18, 2021 | -20.2% | 32 days | 104 days (Mar 17, 2022) |
| Apr 13, 2023 | Jul 7, 2023 | -16.6% | 58 days | 31 days (Aug 21, 2023) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $75.74B
- P/E (TTM)
- 18.2
- EPS, diluted (TTM)
- $40.43
- Revenue (TTM)
- $15.53B
- Dividend yield
- 0.50%
- 52-week range
- $541.00 – $859.34
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $16.07B | $12.17B | $13.12B | $14.20B | $14.34B |
| Gross profit | $13.35B | $10.47B | $10.87B | $12.23B | $12.24B |
| Operating income | $8.95B | $5.39B | $4.35B | $3.99B | $3.58B |
| Net income | $8.08B | $4.34B | $3.95B | $4.41B | $4.50B |
| EPS (diluted) | $71.97 | $38.22 | $34.77 | $38.34 | $41.48 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.72B | $3.79B | $3.03B | $3.68B | $3.75B | $3.88B | $3.61B | $4.29B |
| Net income | $1.34B | $917.7M | $808.7M | $1.39B | $1.46B | $844.6M | $727.2M | $1.30B |
| EPS (diluted) | $11.54 | $8.06 | $7.27 | $12.81 | $13.62 | $7.86 | $6.75 | $12.20 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | $7.08B | $5.01B | $4.59B | $4.42B | $4.98B |
| Capital expenditure | -$551.9M | -$590.1M | -$926.4M | -$755.9M | -$898.4M |
| Free cash flow | $6.53B | $4.42B | $3.67B | $3.66B | $4.08B |
| Dividends paid | $0 | $0 | $0 | $0 | -$370.3M |
| Net share buybacks | -$1.01B | -$1.01B | -$1.09B | -$2.17B | -$3.33B |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $7.99B
- Total assets
- $41.73B
- Total liabilities
- $10.02B
- Total debt
- $1.99B
- Net debt
- -$469.2M
- Shareholders’ equity
- $31.71B
As of Jun 30, 2026 (filed Jul 30, 2026).
Dividends
| Ex-date | Amount | Paid |
|---|---|---|
| Aug 18, 2026 | $0.94 | Aug 31, 2026 |
| May 20, 2026 | $0.94 | Jun 4, 2026 |
| Feb 20, 2026 | $0.94 | Mar 5, 2026 |
| Nov 20, 2025 | $0.88 | Dec 5, 2025 |
| Aug 18, 2025 | $0.88 | Sep 3, 2025 |
| May 20, 2025 | $0.88 | Jun 6, 2025 |
| Feb 20, 2025 | $0.88 | Mar 20, 2025 |
Short interest
- Shares sold short
- 2,526,446
- Days to cover
- 4.42
- Change vs previous report
- -1.0%
FINRA short interest, settlement date Sep 15, 2026.